Transforming growth factor-β and kidney dysfunction

References

• Cheng J, Grande JP. Transforming growth factor-beta signal transduction and progressive renal disease. Exp Biol Med 2002; 227: 943–56
   PubMed Web of Science ®Google Scholar
• Massague J, Gomis RR. The logic of TGFbeta signaling. FEBS Lett 2006; 580: 2811–20
   PubMed Web of Science ®Google Scholar
• Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl 2005; 98: S7–10
   Web of Science ®Google Scholar
• Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600–10
   PubMed Web of Science ®Google Scholar
• Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003; 284: F243–52
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA. Cytokines in kidney disease: the role of transforming growth factor-beta. Am J Kidney Dis 1993; 22: 105–13
   PubMed Web of Science ®Google Scholar
• Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-b in kidney disease. Am J Physiol 1994; 266: F829–42
   PubMed Web of Science ®Google Scholar
• Annes JP, Munger JS, Rifkin DB. Making sense of latent TGFbeta activation. J Cell Sci 2003; 116: 217–24
   PubMed Web of Science ®Google Scholar
• Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-b receptor. Nature 1994; 370: 341–7
   PubMed Web of Science ®Google Scholar
• Huse M, Chen YG, Massague J, Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 1999; 96: 425–36
   PubMed Web of Science ®Google Scholar
• Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massague J. The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell 2001; 8: 671–82
   PubMed Web of Science ®Google Scholar
• Massague J. TGF-b signal transduction. Annu Rev Biochem 1998; 67: 753–91
   PubMed Web of Science ®Google Scholar
• Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 1997; 272: 20572–6
   PubMed Web of Science ®Google Scholar
• Huang SS, Huang JS. TGF-beta control of cell proliferation. J Cell Biochem 2005; 96: 447–62
   PubMed Web of Science ®Google Scholar
• Lebrin F, Deckers M, Bertolino P, Ten Dijke P. TGF-beta receptor function in the endothelium. Cardiovasc Res 2005; 65: 599–608
   PubMed Web of Science ®Google Scholar
• Xu L, Massague J. Nucleocytoplasmic shuttling of signal transducers. Nat Rev Mol Cell Biol 2004; 5: 209–19
   PubMed Web of Science ®Google Scholar
• Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr Opin Cell Biol 2000; 12: 235–43
   PubMed Web of Science ®Google Scholar
• Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685–700
   PubMed Web of Science ®Google Scholar
• Kretzschmar M, Massague J. SMADs: mediators and regulators of TGF-b signaling. Curr Opin Genet Dev 1998; 8: 103–11
   PubMed Web of Science ®Google Scholar
• Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, et al. Identification of Smad7, a TGFb-inducible antagonist of TGFb signalling. Nature 1997; 389: 631–5
   PubMed Web of Science ®Google Scholar
• Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000; 6: 1365–75
   PubMed Web of Science ®Google Scholar
• Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000; 275: 36803–10
   PubMed Web of Science ®Google Scholar
• Runyan CE, Schnaper HW, Poncelet AC. The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-beta1. J Biol Chem 2004; 279: 2632–9
   PubMed Web of Science ®Google Scholar
• Kon A, Vindevoghel L, Kouba DJ, Fujimura Y, Uitto J, Mauviel A. Cooperation between SMAD and NF-kappaB in growth factor regulated type VII collagen gene expression. Oncogene 1999; 18: 1837–44
   PubMed Web of Science ®Google Scholar
• Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, et al. A mechanism of suppression of TGF-b/SMAD signaling by NF-kB/RelA. Genes Dev 2000; 14: 187–97
   PubMed Web of Science ®Google Scholar
• Choi SE, Choi EY, Kim PH, Kim JH. Involvement of protein kinase C and rho GTPase in the nuclear signalling pathway by transforming growth factor-beta1 in rat-2 fibroblast cells. Cell Signal 1999; 11: 71–6
   PubMed Web of Science ®Google Scholar
• Runyan CE, Schnaper HW, Poncelet AC. Smad3 and PKCdelta mediate TGF-beta1-induced collagen I expression in human mesangial cells. Am J Physiol Renal Physiol 2003; 285: F413–22
   PubMed Web of Science ®Google Scholar
• Edlund S, Landstrom M, Heldin CH, Aspenstrom P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 2002; 13: 902–14
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 2001; 12: 27–36
   PubMed Web of Science ®Google Scholar
• Mucsi I, Skorecki KL, Goldberg HJ. Extracellular signal-regulated kinase and the small GTP-binding protein, Rac, contribute to the effects of transforming growth factor-b1 on gene expression. J Biol Chem 1996; 271: 16567–72
   PubMed Web of Science ®Google Scholar
• Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFb/Smad signaling by oncogenic Ras. Genes Dev 1999; 13: 804–16
   PubMed Web of Science ®Google Scholar
• Hayashida T, Poncelet A-C, Hubchak S, Schnaper HW. TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int 1999; 56: 1710–20
   PubMed Web of Science ®Google Scholar
• Atfi A, Djelloul S, Chastre E, Davis R, Gespach C. Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor b-mediated signaling. J Biol Chem 1997; 272: 1429–32
   PubMed Web of Science ®Google Scholar
• Mazars A, Tournigand C, Mollat P, Prunier C, Ferrand N, Bourgeade MF, et al. Differential roles of JNK and Smad2 signaling pathways in the inhibition of c-Myc-induced cell death by TGF-beta. Oncogene 2000; 19: 1277–87
   PubMed Web of Science ®Google Scholar
• Hannigan M, Zhan L, Ai Y, Huang CK. The role of p38 MAP kinase in TGF-beta1-induced signal transduction in human neutrophils. Biochem Biophys Res Commun 1998; 246: 55–8
   PubMed Web of Science ®Google Scholar
• Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, et al. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-induced gene expression. J Biol Chem 1999; 274: 27161–7
   PubMed Web of Science ®Google Scholar
• Nath KA, Grande JP, Croatt A, Haugen J, Kim Y, Rosenberg ME. Redox regulation of renal DNA synthesis, TGF-b1 and collagen gene expression. Kidney Int 1998; 53: 367–81
   PubMed Web of Science ®Google Scholar
• Cheng J, Diaz Encarnacion MM, Warner GM, Gray CE, Nath KA, Grande JP. TGF-beta1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-dependent process. Am J Physiol Cell Physiol 2005; 289: C959–70
   PubMed Web of Science ®Google Scholar
• Kulkarni AB, Huh C-G, Becker D, Geiser A, Lyght M, Flanders KC, et al. Transforming growth factor b-1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993; 90: 770–4
   PubMed Web of Science ®Google Scholar
• Bottinger E, Letterio J, Roberts A. Biology of TGF-beta in knockout and transgenic models. Kidney Int 1997; 51: 1355–60
   PubMed Web of Science ®Google Scholar
• Bartram U, Molin DG, Wisse LJ, Mohamad A, Sanford LP, Doetschman T, et al. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-b(2)-knockout mice. Circulation 2001; 103: 2745–52
   PubMed Web of Science ®Google Scholar
• Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, et al. TGFb2 knockout mice have multiple developmental defects that are non-overlapping with other TGFb knockout phenotypes. Development 1997; 124: 2659–70
   PubMed Web of Science ®Google Scholar
• Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, et al. Abnormal lung development and cleft palate in mice lacking TGF-b 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 1995; 11: 415–21
   PubMed Web of Science ®Google Scholar
• Koo, SH, Cunningham, MC, Arabshahi, B, Gruss, JS, Grant, JH, 3rd. The transforming growth factor-b 3 knock-out mouse: an animal model for cleft palate. Plast Reconstr Surg 2001;108:938–48; discussion 949–51.
   PubMed Web of Science ®Google Scholar
• Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, et al. Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem 2001; 276: 19945–53
   PubMed Web of Science ®Google Scholar
• Molin DG, Poelmann RE, DeRuiter MC, Azhar M, Doetschman T, Gittenberger-de Groot AC. Transforming growth factor beta-SMAD2 signaling regulates aortic arch innervation and development. Circ Res 2004; 95: 1109–17
   PubMed Web of Science ®Google Scholar
• Weinstein M, Yang X, Deng C. Functions of mammalian Smad genes as revealed by targeted gene disruption in mice. Cytokine Growth Factor Rev 2000; 11: 49–58
   PubMed Web of Science ®Google Scholar
• Hamamoto T, Beppu H, Okada H, Kawabata M, Kitamura T, Miyazono K, et al. Compound disruption of smad2 accelerates malignant progression of intestinal tumors in apc knockout mice. Cancer Res 2002; 62: 5955–61
   PubMedGoogle Scholar
• Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-b. Science 1993; 260: 536–9
   PubMed Web of Science ®Google Scholar
• Roberts AB, Piek E, Bottinger EP, Ashcroft G, Mitchell JB, Flanders KC. Is Smad3 a major player in signal transduction pathways leading to fibrogenesis?. Chest 2001; 120(1 Suppl)43S–7
   PubMed Web of Science ®Google Scholar
• Ashcroft G, Yang X, Glick A, Weinstein M, Letterio J, Mizel D, et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nature Cell Biol 1999; 1: 260–6
   PubMed Web of Science ®Google Scholar
• Roberts AB, Tian F, Byfield SD, Stuelten C, Ooshima A, Saika S, et al. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 2006; 17: 19–27
   PubMed Web of Science ®Google Scholar
• Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 2002; 118: 211–5
   PubMed Web of Science ®Google Scholar
• Dunn NR, Koonce CH, Anderson DC, Islam A, Bikoff EK, Robertson EJ. Mice exclusively expressing the short isoform of Smad2 develop normally and are viable and fertile. Genes Dev 2005; 19: 152–63
   PubMedGoogle Scholar
• Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999; 56: 393–405
   PubMed Web of Science ®Google Scholar
• Shankland SJ, Wolf G. Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation, and apoptosis. Am J Physiol Renal Physiol 2000; 278: F515–29
   PubMed Web of Science ®Google Scholar
• Terada Y, Inoshita S, Nakashima O, Kuwahara M, Sasaki S, Marumo F. Cyclins and the cyclin-kinase system—their potential roles in nephrology. Nephrol Dial Transplant 1998; 13: 1913–6
   PubMed Web of Science ®Google Scholar
• Shankland SJ. Cell-cycle control and renal disease. Kidney Int 1997; 52: 294–308
   PubMed Web of Science ®Google Scholar
• Preisig P. A cell cycle-dependent mechanism of renal tubule epithelial cell hypertrophy. Kidney Int 1999; 56: 1193–8
   PubMed Web of Science ®Google Scholar
• Shankland SJ, Al'Douahji M. Cell cycle regulatory proteins in glomerular disease. Exp Nephrol 1999; 7: 207–11
   PubMedGoogle Scholar
• Johnson D, Walker C. Cyclins and cell cycle checkpoints. Ann Rev Pharmacol 1999; 39: 295–312
   Google Scholar
• Rao R. Targets for cancer therapy in the cell cycle pathway. Curr Opin Oncol 1996; 8: 516–24
   PubMedGoogle Scholar
• Alexandrow MG, Moses HL. Transforming growth factor b and cell cycle regulation. Cancer Res 1995; 55: 1452–7
   PubMed Web of Science ®Google Scholar
• Polyak K. Negative regulation of cell growth by TGF-b. Biochem Biophys Acta 1996; 1242: 185–99
   PubMed Web of Science ®Google Scholar
• Young BA, Johnson RJ, Alpers C, Eng E, Gordon K, Floege J, et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995; 47: 935–44
   PubMed Web of Science ®Google Scholar
• Shankland SJ, Pippin J, Flanagan M, Coats SR, Nangaku M, Gordon KL, et al. Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int 1997; 51: 1088–99
   PubMed Web of Science ®Google Scholar
• Wolf G, Schroeder R, Zahner G, Stahl RA, Shankland SJ. High glucose-induced hypertrophy of mesangial cells requires p27(Kip1), an inhibitor of cyclin-dependent kinases. Am J Pathol 2001; 158: 1091–100
   PubMed Web of Science ®Google Scholar
• Shankland SJ, Hugo C, Coats SR, Nangaku M, Pichler RH, Gordon KL, et al. Changes in cell-cycle protein expression during experimental mesangial proliferative glomerulonephritis. Kidney Int 1996; 50: 1230–9
   PubMed Web of Science ®Google Scholar
• Al-Douahji M, Brugarolas J, Brown PA, Stehman-Breen CO, Alpers CE, Shankland SJ. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 1999; 56: 1691–9
   PubMed Web of Science ®Google Scholar
• Roberts A, Sporn M. Physiological actions and clinical applications of transforming growth factor-beta. Growth Factors 1993; 8: 1–9
   PubMed Web of Science ®Google Scholar
• Suzumura A, Sawada M, Yamamoto H, Marunouchi T. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J Immunol 1993; 151: 2150–8
   PubMed Web of Science ®Google Scholar
• Shrikant P, Lee SJ, Kalvakolanu I, Ransohoff RM, Benveniste EN. Stimulus-specific inhibition of intracellular adhesion molecule-1 gene expression by TGF-beta. J Immunol 1996; 157: 892–900
   PubMed Web of Science ®Google Scholar
• Winkler MK, Beveniste EN. Transforming growth factor-beta inhibition of cytokine-induced vascular cell adhesion molecule-1 expression in human astrocytes. Glia 1998; 22: 171–9
   PubMed Web of Science ®Google Scholar
• Cheon H, Yu SJ, Yoo DH, Chae IJ, Song GG, Sohn J. Increased expression of pro-inflammatory cytokines and metalloproteinase-1 by TGF-beta1 in synovial fibroblasts from rheumatoid arthritis and normal individuals. Clin Exp Immunol 2002; 127: 547–52
   PubMed Web of Science ®Google Scholar
• Border WA, Noble NA. TGF-b in kidney fibrosis: a target for gene therapy. Kidney Int 1997; 51: 1388–96
   PubMed Web of Science ®Google Scholar
• Schneider A, Panzer U, Zahner G, Wenzel U, Wolf G, Thaiss F, et al. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-b. Kidney Int 1999; 56: 135–44
   PubMed Web of Science ®Google Scholar
• Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor b1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271: 17779–84
   PubMed Web of Science ®Google Scholar
• Gharaee-Kermani M, McCullumsmith RE, Charo IF, Kunkel SL, Phan SH. CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine 2003; 24: 266–76
   PubMed Web of Science ®Google Scholar
• Roberts IS, Burrows C, Shanks JH, Venning M, McWilliam LJ. Interstitial myofibroblasts: predictors of progression in membranous nephropathy. J Clin Pathol 1997; 50: 123–7
   PubMed Web of Science ®Google Scholar
• Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999; 277: C1–9
   PubMed Web of Science ®Google Scholar
• Badid C, Desmouliere A, Babici D, Hadj-Aissa A, McGregor B, Lefrancois N, et al. Interstitial expression of alpha-SMA: an early marker of chronic renal allograft dysfunction. Nephrol Dial Transplant 2002; 17: 1993–8
   PubMed Web of Science ®Google Scholar
• Goumenos DS, Tsamandas AC, Oldroyd S, Sotsiou F, Tsakas S, Petropoulou C, et al. Transforming growth factor-b1 and myofibroblasts: a potential pathway towards renal scarring in human glomerular disease. Nephron 2001; 87: 240–8
   PubMed Web of Science ®Google Scholar
• Lan HY. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003; 12: 25–9
   PubMed Web of Science ®Google Scholar
• Valette L, Prigent AF, Nemoz G, Anker G, Macovschi O, Lagarde M. Concanavalin A stimulates the rolipram-sensitive isoforms of cyclic nucleotide phosphodiesterase in rat thymic lymphocytes. Biochem Biophys Res Commun 1990; 169: 864–72
   PubMed Web of Science ®Google Scholar
• Collins MKL, Perkins GR, Rodriguez-Tarduchy G, Nieto MA, Lopez-Rivas A. Growth factors as survival factors: regulation of apoptosis. Bioessays 1994; 16: 133–8
   PubMed Web of Science ®Google Scholar
• Horster MF, Braun GS, Huber SM. Embryonic renal epithelia: induction, nephrogenesis, and cell differentiation. Physiol Rev 1999; 79: 1157–91
   PubMed Web of Science ®Google Scholar
• Strutz F, Okada H, Lo CW, Danoff T, Carone RL, Tomaszewski JE, et al. Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 1995; 130: 393–405
   PubMed Web of Science ®Google Scholar
• Ng YY, Huang TP, Yang WC, Chen ZP, Yang AH, Mu W, et al. Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int 1998; 54: 864–76
   PubMed Web of Science ®Google Scholar
• Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465–75
   PubMed Web of Science ®Google Scholar
• Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002; 13: 96–107
   PubMed Web of Science ®Google Scholar
• Ng YY, Fan JM, Mu W, Nikolic-Paterson DJ, Yang WC, Huang TP, et al. Glomerular epithelial-myofibroblast transdifferentiation in the evolution of glomerular crescent formation. Nephrol Dial Transplant 1999; 14: 2860–72
   PubMed Web of Science ®Google Scholar
• Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341–50
   PubMed Web of Science ®Google Scholar
• Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001; 108: 1853–63
   PubMed Web of Science ®Google Scholar
• Li Y, Yang J, Dai C, Wu C, Liu Y. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest 2003; 112: 503–16
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964–8
   PubMed Web of Science ®Google Scholar
• Jinde K, Nikolic-Paterson DJ, Huang XR, Sakai H, Kurokawa K, Atkins RC, et al. Tubular phenotypic change in progressive tubulointerstitial fibrosis in human glomerulonephritis. Am J Kidney Dis 2001; 38: 761–9
   PubMed Web of Science ®Google Scholar
• Takayama H, Trenn G, Sitkovsky MV. Locus of inhibitory action of cAMP-dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway. J Biol Chem 1987; 263: 2330–6
   Web of Science ®Google Scholar
• Wolman SR. Fluorescence in situ hybridization: a new tool for the pathologist. Hum Pathol 1994; 25: 586–90
   PubMed Web of Science ®Google Scholar
• Troxel DB, Sabella JD. Problem areas in pathology practice uncovered by a review of malpractice claims. Am J Surg Pathol 1994; 18: 821–31
   PubMed Web of Science ®Google Scholar
• Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, et al. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int 2002; 61: 1714–28
   PubMed Web of Science ®Google Scholar
• Cheng S, Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003; 162: 1937–49
   PubMed Web of Science ®Google Scholar
• Gore-Hyer E, Shegogue D, Markiewicz M, Lo S, Hazen-Martin D, Greene EL, et al. TGF-b and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 2002; 283: F707–16
   PubMed Web of Science ®Google Scholar
• Yang J, Dai C, Liu Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002; 13: 2464–77
   PubMed Web of Science ®Google Scholar
• Okada H, Danoff TM, Kalluri R, Neilson EG. Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 1997; 273: F563–74
   PubMed Web of Science ®Google Scholar
• Fan JM, Ng YY, Hill PA, Nikolic-Paterson DJ, Mu W, Atkins RC, et al. Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int 1999; 56: 1455–67
   PubMed Web of Science ®Google Scholar
• Dai C, Yang J, Liu Y. Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J Biol Chem 2003; 278: 12537–45
   PubMed Web of Science ®Google Scholar
• Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 2002; 13: 1464–72
   PubMed Web of Science ®Google Scholar
• Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002; 283: F861–75
   PubMed Web of Science ®Google Scholar
• Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003; 112: 1486–94
   PubMed Web of Science ®Google Scholar
• Brown Z, Strieter RM, Neild GH, Thompson RC, Kunkel SL, Westwick J. IL-1 receptor antagonist inhibits monocyte chemotactic peptide 1 generation by human mesangial cells. Kidney Int 1992; 42: 95–101
   PubMed Web of Science ®Google Scholar
• Lianos EA, Orphanos V, Cattell V, Cook T, Anagnou N. Glomerular expression and cell origin of transforming growth factor-beta1 in anti-glomerular basement membrane disease. Am J Med Sci 1994; 307: 1–6
   PubMed Web of Science ®Google Scholar
• Fukasawa H, Yamamoto T, Suzuki H, Togawa A, Ohashi N, Fujigaki Y, et al. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int 2004; 65: 63–74
   PubMed Web of Science ®Google Scholar
• Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, et al. Inhibition of TGF-b1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996; 50: 148–55
   PubMed Web of Science ®Google Scholar
• Zhou A, Ueno H, Shimomura M, Tanaka R, Shirakawa T, Nakamura H, et al. Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int 2003; 64: 92–101
   PubMed Web of Science ®Google Scholar
• Huijun W, Long C, Zhigang Z, Feng J, Muyi G. Ex vivo transfer of the decorin gene into rat glomerulus via a mesangial cell vector suppressed extracellular matrix accumulation in experimental glomerulonephritis. Exp Mol Pathol 2005; 78: 17–24
   PubMed Web of Science ®Google Scholar
• Ma L, Fogo AB. Role of angiotensin II in glomerular injury. Semin Nephrol 2001; 21: 544–53
   PubMed Web of Science ®Google Scholar
• Daniel C, Takabatake Y, Mizui M, Isaka Y, Kawashi H, Rupprecht H, et al. Antisense oligonucleotides against thrombospondin-1 inhibit activation of tgf-beta in fibrotic renal disease in the rat in vivo. Am J Pathol 2003; 163: 1185–92
   PubMed Web of Science ®Google Scholar
• Lan HY, Mu W, Tomita N, Huang XR, Li JH, Zhu HJ, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol 2003; 14: 1535–48
   PubMed Web of Science ®Google Scholar
• Klahr, S, Morrissey, J. Obstructive nephropathy and renal fibrosis: the role of bone morphogenic protein-7 and hepatocyte growth factor. Kidney Int Suppl 2003:S105–12.
   Google Scholar
• Li T, Surendran K, Zawaideh MA, Mathew S, Hruska KA. Bone morphogenetic protein 7: a novel treatment for chronic renal and bone disease. Curr Opin Nephrol Hypertens 2004; 13: 417–22
   PubMed Web of Science ®Google Scholar
• Hirschberg R. Wound healing in the kidney: complex interactions in renal interstitial fibrogenesis. J Am Soc Nephrol 2005; 16: 9–11
   PubMed Web of Science ®Google Scholar
• Yang J, Dai C, Liu Y. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. J Am Soc Nephrol 2005; 16: 68–78
   PubMed Web of Science ®Google Scholar
• Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004; 287: F7–16
   PubMed Web of Science ®Google Scholar